BfArM publishes Medtronic urgent field safety notice for Vanta implantable neurostimulator
Germany's regulator has posted a manufacturer advisory on the Vanta INS, but the published listing does not describe the issue or the actions required.
The German Federal Institute for Drugs and Medical Devices (BfArM) has published an Urgent Field Safety Notice from Medtronic Inc concerning the Vanta Implantable Neurostimulator (INS). The notice is dated 10 November 2026.
BfArM classifies the product under active implantable medical devices, specifically biostimulators. The entry carries the reference 16418/23.
The BfArM listing contains no description of the problem, the affected devices or batches, or the corrective measures. It simply refers readers to the manufacturer's Advisory Notice, which is attached as a 404 KB PDF. BfArM flags that the file does not meet accessibility standards.
As general context, a field safety notice is the communication a manufacturer sends to users and other relevant parties when it takes a field safety corrective action on a marketed device. National authorities such as BfArM often make these notices publicly available.
Because the text available here does not set out the safety issue, its severity or any instructions for clinicians and patients, those details can only be confirmed from the Advisory Notice itself.
What it means for your team
- Obtain and read the full Medtronic Advisory Notice via BfArM; the public listing gives no detail on the issue, affected units or required actions.
- Quality and vigilance teams at healthcare providers and distributors should check whether Vanta INS devices are in their inventory or among their patients, and follow the manufacturer's instructions.
- Regulatory affairs teams tracking active implantable devices should log reference 16418/23 and the 10 November 2026 publication date for their records.
Official source: BfArM field safety notices ↗
Article written by VigiEye from the official source (BfArM field safety notices). AI-assisted; check the source before acting.